FGF14-AS1: A Potential Drug Target and Biomarker (G100874081)

Target Name: FGF14-AS1

NCBI ID: G100874081

FGF14-AS1

Other Name(s): FGF14 antisense RNA 1

FGF14-AS1: A Potential Drug Target and Biomarker

Fibroblast growth factor (FGF) is a cytoskeletal protein that plays a crucial role in cell growth, development, and repair. FGF signaling has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, targeting FGF signaling has become an attractive research focus in the fields of genetics, pharmacology, and biochemistry. One promising lead in this field is FGF14-AS1, a potential drug target and biomarker.

FGF14-AS1 is a 19-kDa transmembrane protein that is expressed in various tissues, including brain, heart, liver, and pancreas. It is a potent regulator of cell proliferation, differentiation, and survival, and has been implicated in the development and progression of various diseases.

One of the most significant functions of FGF14-AS1 is its role in cancer. FGF14-AS1 has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and prostate cancer. It has also been shown to contribute to the development of cancer stem cells, which are capable of self-replication and have the potential to promote tumor progression.

FGF14-AS1 has also been linked to neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells, which can lead to a range of symptoms, including cognitive decline, hallucinations, and progressive muscle weakness. FGF14-AS1 has been shown to promote the growth of neuroblastoma cells, which are a common type of cancer that originates from neural stem cells.

In addition to its role in cancer and neurodegenerative diseases, FGF14-AS1 has also been implicated in the development of developmental disorders. FGF14-AS1 has been shown to be involved in the development of Down syndrome, a genetic disorder that is characterized by a range of developmental and cognitive impairments.

FGF14-AS1 has also been shown to play a role in the regulation of inflammation and immune response. It has been shown to regulate the production of pro-inflammatory cytokines, which can contribute to the development of inflammatory diseases.

Despite its potential as a drug target, FGF14-AS1 has not yet been extensively studied, and much of its function and regulation remains unexplored. However, the potential implications of FGF14-AS1 as a drug target and biomarker make it an attractive area of research for future study.

In conclusion, FGF14-AS1 is a promising drug target and biomarker that has the potential to contribute to the development of new treatments for cancer, neurodegenerative diseases, and developmental disorders. Further research is needed to fully understand its function and regulation, and to explore its potential as a drug.

Protein Name: FGF14 Antisense RNA 1

The "FGF14-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FGF14-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets